CathWorks Unveils Exciting Events for EuroPCR 2025 Conference in Paris

CathWorks Unveils Key Events at EuroPCR 2025

CathWorks, a frontrunner in digital health innovations, has revealed an engaging schedule for the EuroPCR 2025 conference, set to take place from May 20 to May 23 at the Palais des Congrès in Paris, France. The company is keen to showcase its cutting-edge FFRangio technology, which significantly alters the landscape of cardiovascular diagnostics and treatment.

During the conference, a pivotal presentation will be delivered by Dr. Toru Tanigaki from Gifu Heart Center in Japan. He will present the one-year outcomes of the PROVISION1 study, a groundbreaking Japanese randomized controlled trial comparing clinical outcomes of FFRangio guidance against traditional invasive FFR methods. This presentation promises to unveil insights into the effectiveness and advantages of the non-invasive FFRangio technology.

Moreover, an educational symposium titled "The New Global Era of Patient Care with CathWorks FFRangio" is scheduled for Thursday afternoon, featuring Dr. Rasha Al-Lamee from Imperial College London as the anchorperson alongside Professor Ran Kornowski from Rabin Medical Center in Israel as the spokesperson. Attendees can look forward to a rich lineup of esteemed faculty, including renowned experts Dr. Benjamin Honton, Dr. Thomas Keeble, Dr. Stephane Fournier, and Professor Hitoshi Matsuo, who will address the integration and adoption of the FFRangio system across various healthcare settings.

In addition to these presentations, the CathWorks FFRangio system will be accessible for hands-on demonstrations during the "Meet the Expert" sessions at the Medtronic booth. This collaborative effort with Medtronic has significantly boosted the adoption of the FFRangio system globally, further establishing it within cardiac catheterization labs.

Ramin Mousavi, President and CEO of CathWorks, expressed excitement about the imminent presence at EuroPCR, emphasizing the strategic partnership with Medtronic to integrate FFRangio technology as a standard of care worldwide. He stated, "Our efforts are geared toward collaborating with the interventional cardiology community to ensure FFRangio becomes a universally accepted standard of care."

The CathWorks FFRangio® System integrates advanced artificial intelligence with computational science, transforming cardiac disease diagnostics. By deriving physiological data from routine angiograms, it eliminates the need for invasive pressure wires and drug stimulation, offering clinicians instant and reliable FFRangio values for the complete coronary network.

For those looking to dive deeper into the advancements in cardiovascular care, CathWorks invites all conference participants to visit their booth and engage with healthcare professionals about the transformative potential of the FFRangio system. As the healthcare landscape evolves, CathWorks continues to lead the charge in making significant strides in patient care, offering innovative solutions designed to enhance treatment and outcomes for those afflicted with cardiovascular disease. For more information about CathWorks, visit www.cath.works and follow them on LinkedIn at @CathWorks.

As the anticipation builds around EuroPCR 2025, stakeholders in the cardiology field are eager to see how the integration of cutting-edge technologies like those offered by CathWorks can enhance patient care and outcomes in the cardiovascular domain, marking a new chapter in global health innovation.